Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.

Lattanzio L, Denaro N, Vivenza D, Varamo C, Strola G, Fortunato M, Chamorey E, Comino A, Monteverde M, Lo Nigro C, Milano G, Merlano M.

Cancer Immunol Immunother. 2017 May;66(5):573-579. doi: 10.1007/s00262-017-1960-8. Epub 2017 Feb 14.

PMID:
28197666
2.

Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.

Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, Lo Nigro C, Nagano A, Wang J, Chelala C, Szlosarek P, Martin SA.

Cell Rep. 2016 Aug 9;16(6):1604-1613. doi: 10.1016/j.celrep.2016.06.097. Epub 2016 Jul 21.

3.

Reoxygenation Reverses Hypoxia-related Radioresistance in Head and Neck Cancer Cell Lines.

Tonissi F, Lattanzio L, Astesana V, Cavicchioli F, Ghiglia A, Monteverde M, Vivenza D, Gianello L, Russi E, Merlano M, Lo Nigro C.

Anticancer Res. 2016 May;36(5):2211-5.

PMID:
27127125
4.

E1 detection as prognosticator in human papillomavirus-positive head and neck cancers.

Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.

Int J Biol Markers. 2016 Apr-Jun;31(2):0. doi: 10.5301/jbm.5000193. Epub 2016 Mar 22.

PMID:
27040135
5.

Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.

Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.

Anticancer Drugs. 2016 Jul;27(6):533-9. doi: 10.1097/CAD.0000000000000360.

PMID:
26982238
6.

Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.

Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M.

Int J Biol Markers. 2016 May 28;31(2):e183-92. doi: 10.5301/jbm.5000192.

PMID:
26916894
7.

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.

Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.

Invest New Drugs. 2015 Aug;33(4):801-9. doi: 10.1007/s10637-015-0249-z. Epub 2015 May 7.

PMID:
25947567
8.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Review.

PMID:
25819749
9.

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2015 Apr;33(2):310-20. doi: 10.1007/s10637-015-0210-1. Epub 2015 Jan 22.

PMID:
25603975
10.

MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.

Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C.

Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126.

PMID:
25588856
11.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

12.

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma.

Messa F, Tonissi F, Millo E, Bracco E, Ungari S, Lattanzio L, Merlano M, Damonte G, Lo Nigro C.

Int J Biol Markers. 2014 Mar 24;29(1):e55-61. doi: 10.5301/jbm.5000052.

PMID:
24242294
13.

Role of IL-8 induced angiogenesis in uveal melanoma.

Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C.

Invest New Drugs. 2013 Oct;31(5):1107-14. doi: 10.1007/s10637-013-0005-1. Epub 2013 Aug 4.

PMID:
23912257
14.

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.

J Invest Dermatol. 2013 May;133(5):1278-85. doi: 10.1038/jid.2012.493. Epub 2013 Feb 14.

15.

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T.

Cell Death Dis. 2013 Jan 17;4:e458. doi: 10.1038/cddis.2012.197.

16.

Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano MC, Lo Nigro C.

Anticancer Drugs. 2013 Feb;24(2):120-30. doi: 10.1097/CAD.0b013e328358d1dc.

PMID:
22990129
17.

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T.

Br J Cancer. 2012 Oct 9;107(8):1423-32. doi: 10.1038/bjc.2012.380. Epub 2012 Sep 6.

18.

Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.

Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 Jul 10.

19.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791
20.

NT5E CpG island methylation is a favourable breast cancer biomarker.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

21.

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.

22.

Abdominal compartment syndrome due to a giant multilobulated ovarian serous cystadenoma. Case report and review of the literature.

Merlicco D, Roggia G, Lombardi M, Lattanzio L, Marzaioli R, Nacchiero M.

Ann Ital Chir. 2012 Nov-Dec;83(6):563-6. Review.

PMID:
22615039
23.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
24.

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.

Br J Cancer. 2012 Apr 10;106(8):1446-52. doi: 10.1038/bjc.2012.95. Epub 2012 Mar 27.

25.

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.

Oral Oncol. 2012 Jul;48(7):602-7. doi: 10.1016/j.oraloncology.2012.01.022. Epub 2012 Feb 21.

PMID:
22356895
26.

Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.

Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T.

Leuk Lymphoma. 2012 Sep;53(9):1709-13. doi: 10.3109/10428194.2012.661854. Epub 2012 Mar 13.

PMID:
22288719
27.

High frequency of complex TP53 mutations in CNS metastases from breast cancer.

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T.

Br J Cancer. 2012 Jan 17;106(2):397-404. doi: 10.1038/bjc.2011.464. Epub 2011 Dec 20.

28.

Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

Int J Oncol. 2010 Nov;37(5):1219-28.

PMID:
20878069
29.

Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis.

Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, Lo Nigro C, Crook T, Machesky LM, Gusterson BA.

Am J Pathol. 2010 Nov;177(5):2323-33. doi: 10.2353/ajpath.2010.100209. Epub 2010 Sep 16.

30.

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

J Clin Invest. 2010 Aug;120(8):2842-57. doi: 10.1172/JCI36125. Epub 2010 Jul 1.

31.

Impact of erythropoietin on the effects of irradiation under hypoxia.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

PMID:
19499245
32.

Zinc content of red and white blood cells in aboriginal children.

Cheek DB, Hay HJ, Lattanzio L, Ness D, Ludwigsen N, Spargo R.

Aust N Z J Med. 1984 Oct;14(5):638-42.

PMID:
6099114
33.

Supplemental Content

Loading ...
Support Center